Description: Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
Home Page: jouncetx.com
JNCE Technical Analysis
780 Memorial Drive
Cambridge,
MA
02139
United States
Phone:
857 259 3840
Officers
| Name | Title |
|---|---|
| Dr. Richard Murray Ph.D. | Pres, CEO & Director |
| Mr. Hugh M. Cole | Chief Operating Officer |
| Dr. Elizabeth G. Trehu M.D. | Chief Medical Officer |
| Dr. James Patrick Allison Ph.D. | Founder |
| Dr. Thomas F. Gajewski M.D., Ph.D. | Founder |
| Dr. Robert D. Schreiber Ph.D. | Founder |
| Dr. Drew Mark Pardoll M.D., Ph.D. | Founder |
| Dr. Padmanee Sharma M.D., Ph.D. | Founder |
| Dr. Louis M. Weiner M.D. | Founder |
| Ms. Kimberlee Cobleigh Drapkin CPA, CPA | CFO & Treasurer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 19.4553 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2749 |
| Price-to-Sales TTM: | 7.272 |
| IPO Date: | 2017-01-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 137 |